July's eNews is here to help you unveil the latest insights for advancing our Life Science Cluster!
News
• Pioneering partnership will see the delivery of 95,000 square feet of incubator space on the South Bank of London
• Split across two sites, the life sciences facilities will help incubate early-stage companies spun out of King’s College London in a boost for UK life sciences
• Announcement comes just weeks after the government launched a package of measures to turbocharge growth in UK life sciences
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR ANNOUNCES ADDITIONAL AGREEMENT WITH LEADING BIOPHARMACEUTICAL COMPANY
Cambridge, UK, 5 July 2023. Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has entered into an agreement with a leading biopharmaceutical company to support the ongoing development of a biosimilar product.
Members of the Domainex team supported their local community by volunteering at Sawston Village College. They helped to paint fences, build raised flower beds and did plenty of weeding! Check out the team photo on the Domainex Twitter page!
The DIAMOND Study
The Quadram Institute are looking for volunteers, based in the UK, to take part in a study investigating how our genes and diet influence the risk of dementia, and the role of the gut microbiome in this.
This study can be carried out fully remotely from your own home.
Suzanne Holden, Vice President, Corporate Accounts & Country Leader United Kingdom at Thermo Fisher Scientific, shares her thoughts on why she is excited about the research and investment in predictive genomics. Read this short article that discusses: addressing unmet needs, improving patient outcomes; polygenic risk scores - stratifying the population and from drug discovery to clinical though validation: 'The future, now: Revolutionising disease prevention through predictive
London, July 3rd - Kadans Science Partner will add Harrow House in Oxford, UK to its Pan-European portfolio. The asset will be acquired from Oxford Biomedica in a sale and lease back transaction. Harrow House is a purpose-built manufacturing facility which will be leased back, in its entirety, to Oxford Biomedica. Oxford Biomedica is a quality and innovation-led viral vector CDMO, providing development and manufacturing expertise to some of the world’s most innovative pharmaceutical and biotechnology companies.
Stevenage Bioscience Catalyst is a renowned hub for life sciences in the UK and is recognised as being on par with other established EU clusters specialising in cell and gene therapy.
Read more about how their exciting developments and opportunities for collaboration is making them a centre for excellence.
- PrecisionLife to analyse OXEGENE data to improve mechanistic understanding of endometriosis and identify novel drug targets to support the development of new personalised treatments for millions of women worldwide.
Oxford, UK, 29 June 2023 – PrecisionLife, a leading techbio company driving precision medicine in complex chronic diseases, announced today a data access agreement with the University of Oxford to license the Oxford Endometriosis Gene (OXEGENE) dataset with the aim to develop new personalised treatments for endometriosis patients.
Planning Submitted at 4 Brandon Road, Kings Cross
Designed collaboratively with the Kadans in-house team and DMA, the building sits adjacent to the existing 5-10 Brandon Road to provide a range of complimentary spaces.
The proposal at 4 Brandon Road is five storeys of flexible lab space with the addition of basement and roof plant. Designed with adaptability at the core, the floorplates are arranged on a regular grid to minimise vibration and maximise usable space.